• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Avalyn iniates Phase 2b MIST study of AP01 inhaled pirfenidone in PPF patients

Avalyn Pharma has announced the initiation of the Phase 2b MIST study of AP01 pirfenidone inhalation solution in patients with progressive pulmonary fibrosis (PPF). In March 2023, the company announced that a Phase 1b trial of nebulized AP01 in IPF patients demonstrated a significant reduction in the progression of the disease, with lung function in most patients basically stabilized. The year-long Phase 2b trial is expected to enroll 300 PFF patients and will compare 2 dose levels of AP01 to placebo.

In addition to AP01, Avalyn is developing AP02 inhaled nintedanib for the treatment of pulmonary fibrosis and recently initiated a Phase 1b trial of AP02 in healthy adults. According to the company’s web site, Avalyn also intends to develop an inhaled fixed dose combination of nintedanib and pirfenidone.

Avalyn CEO Lyn Baranowski commented, “We are thrilled to start this Phase 2b study of AP01, which marks another significant milestone for Avalyn and our commitment to advancing inhaled treatments for patients with pulmonary fibrosis. We are encouraged by AP01’s robust clinical data generated to date, which demonstrated strong tolerability and efficacy with inhaled delivery of pirfenidone. We would like to extend our sincere gratitude to the pulmonary fibrosis community of health care practitioners, patients, and their caregivers for their ongoing support of our efforts to develop an innovative therapeutic option for people living this life-threatening disease.”

Read the Avalyn Pharma press release.

Share

published on September 4, 2024

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews